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Abstract
Objectives: We sought to define regional variations in fluoroquinolone non-susceptibility (FQ-NS) among
bloodstream isolates of Escherichia coli across the Veterans Health Administration (VHA) in the United States.
Methods: We analyzed a retrospective cohort of patients managed at 136 VHA hospitals who had a blood culture
positive for E.coli between 2003 and 2013. Hospitals were classified based on US Census Divisions, and regional
variations in FQ-NS were analyzed.
Results: Twenty-four thousand five hundred twenty-three unique E.coli bloodstream infections (BSIs) were
identified between 2003 and 2013. 53.9 % of these were community-acquired, 30.7 % were healthcare-associated,
and 15.4 % were hospital-onset BSIs. The proportion of E.coli BSIs with FQ-NS significantly varied across US Census
Divisions (p < 0.001). During 2003–2013, the proportion of E.coli BSIs with FQ-NS was highest in the West South-
Central Division (32.7 %) and lowest in the Mountain Division (20.0 %). Multivariable analysis showed that there
were universal secular trends towards higher FQ-NS rates (p < 0.001) with significant variability of slopes across US
Census Divisions (p < 0.001).
Conclusion: There has been a universal increase in FQ-NS among E.coli BSIs within VHA, but the rate of increase
has significantly varied across Census Divisions. The reasons for this variability are unclear. These findings reinforce
the importance of using local data to develop and update local antibiograms and antibiotic-prescribing guidelines.
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Introduction
Fluoroquinolones are a synthetic class of antibiotics that
have been used in clinical medicine since the 1970s.
Fluoroquinolones have excellent oral bioavailability,
provide a broad-spectrum of antibacterial activity, and
are highly efficacious in the treatment of a variety of
infections. However, the overuse of these agents has led
to rising rates of FQ non-susceptibility (FQ-NS) [1–3].
Historically, fluoroquinolones have been reliably active
against Escherichia coli, a common cause of urinary tract
infections, bloodstream infections, and intra-abdominal
infections. National antibiotic-prescribing guidelines still
recommend the empiric use of fluoroquinolones for
infections that commonly involve E.coli [4, 5], but given
the rising prevalence of FQ-NS, the empiric use of fluor-
oquinolones may no longer be appropriate in some
geographic regions [1–3].
In this study, we sought to define regional variations in
FQ-NS among bloodstream isolates of E.coli in the
Veterans Health Administration (VHA) over an 11-year
period. Identifying temporal and regional differences in
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resistance patterns may inform development of national
versus regional or local treatment guidelines.
Methods
We constructed a retrospective cohort of all patients
within the VHA who had a blood culture positive for
E.coli between January 1, 2003 and December 31, 2013.
Data from 136 acute care hospitals in 48 US states
contributed to the cohort. FQ-NS was defined as a non-
susceptible result to at least one FQ: ciprofloxacin,
levofloxacin, and/or moxifloxacin. In line with guidelines
from the Clinical and Laboratory Standards Institute,
only the first isolate was included when the patient had
more than one blood culture positive for E. coli in the
same calendar year [6].
Bloodstream infections (BSIs) were defined as
hospital-onset, healthcare-associated, or community-
acquired. Hospital-onset BSIs were defined as an E.coli-
positive blood culture that was obtained after the patient
had been hospitalized for ≥48 h. Healthcare-associated
BSIs were defined as an E.coli-positive blood culture
obtained at the time of admission or <48 h of admission
if the patient met established criteria for healthcare
exposure [7]. Community-acquired BSIs were defined as
E.coli-positive blood cultures obtained at the time of
admission or <48 h of admission in patients who did not
meet criteria for healthcare-associated infections.
Hospitals were regionalized based on US Census Divi-
sions (https://www.census.gov/geo/reference/gtc/gtc_cen
sus_divreg.html), and annual averages of FQ-NS were
mapped. Monthly and annual counts of isolates with and
without FQ-NS were measured as outcomes.
Poisson regression models were used to predict the
number of isolates with FQ-NS while incorporating total
number of isolates as an offset variable. The generalized
estimating equations (GEE) method was used to account
for grouping effect within Census Divisions. Residual
plots were inspected to ensure the appropriateness of all
models. An interaction term between time and region
was included in the model, and region-specific incidence
rate ratios (IRRs) by month and year were estimated to
assess variability of slopes across divisions.
Results
Twenty-four thousand five hundred twenty-three unique
E.coli (BSIs) were identified between 2003 and 2013
across 136 hospitals and 9 Census Divisions (Table 1). A
majority of these BSIs were classified as community-
acquired (53.9 %); 30.7 % were healthcare-associated and
15.4 % were hospital-onset BSIs.
The prevalence of FQ-NS increased with healthcare
exposure. The frequency of FQ-NS was 20.2 % for
community-acquired E.coli-BSIs, 37.0 % for healthcare-
associated E.coli-BSIs, and 37.7 % for hospital-onset
E.coli-BSIs.
Throughout the VHA, the percentage of E.coli-BSIs
with FQ-NS increased from 13.9 % in 2003 to 31.3 % in
2008 and 32.6 % in 2013. Among E.coli strains demon-
strating FQ-NS, the frequency of non-susceptibility to
other antibiotic classes was as follows: 16.6 % extended-
spectrum cephalosporins, 34.4 % aminoglycosides, and
0.3 % carbapenems.
The proportion of E.coli-BSIs with FQ-NS signifi-
cantly varied across Census Divisions (range: 20.0–
32.7 %; p < 0.001). During 2003–2013, the proportion of
E.coli BSIs with FQ-NS was highest in the West South
Central Division (32.7 %) and lowest in the Mountain
Division (20.0 %, Fig. 1). In 2013 alone, the highest
frequency of FQ-NS among E.coli-BSIs was seen in the
East South Central Division (39.6 %) and the lowest
frequency of FQ-NS was seen in the Pacific Central
Division (25.4 %).
Regression analysis showed that there were universal
temporal trends towards higher FQ-NS rates (p < 0.001)
with significant variability of slopes across Census
Divisions (p < 0.001, Fig. 2). The annual mean rate of
increase in FQ-NS was as follows: East North Central
0.41 % /month; Mountain 0.86 % /month; South Atlantic
0.54 % /month; East South Central 0.51 % /month; New
England 0.44 % /month; West North Central 0.89 %
/month; Middle Atlantic 0.45 % /month; Pacific Central
0.19 % /month; West South Central 0.40 % /month.
Discussion
Our study has demonstrated a sustained increase in the
frequency of FQ-NS among E.coli BSIs across VHA
during 2003–2013. The rate of change has significantly
varied across Census Divisions. The high prevalence of
FQ-NS in some divisions could influence the empiric
use of fluoroquinolones for infections thought to involve
Table 1 Number of VHA hospitals and E.coli bloodstream
isolates (BSIs) from each census region, 2003–2013
Census region Number of hospitals Number of included
E. coli BSIs (%)
East North Central 18 2799 (11.4 %)
East South Central 11 2146 (8.8 %)
Middle Atlantic 18 2544 (10.4 %)
Mountain 13 2010 (8.2 %)
New England 7 783 (3.2 %)
Pacific Central 13 3253 (13.3 %)
South Atlantic 26 5358 (21.8 %)
West North Central 16 1896 (7.7 %)
West South Central 14 3734 (15.2 %)
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E.coli and suggests that regional or even local guidelines
might be preferred over national guidelines.
The clonal expansion of sequence type (ST) 131 E.coli
is likely a major driver of this rising prevalence of fluoro-
quinolone resistance [8–11]. ST131 represents one of
more than 1000 STs of E.coli defined by multilocus
sequence typing (MLST). The clonal expansion of
ST131 has been a global phenomenon that has not
spared the VHA. In a 2011 analysis of E.coli clinical iso-
lates from 24 VHA medical centers, ST131 accounted
for 78 % of fluoroquinolone-resistant isolates and 28 %
of all isolates [12]. The aminoglycoside and carbapenem
susceptibility profiles of ST131 strains described in this
2011 study are similar to that of FQ-NS strains in our
report. Studies outside of VHA have also found that
ST131 accounts for 70–80 % of fluoroquinolone-
resistant E.coli infections [12–14]. A specific subclone,
which represents the vast majority of fluoroquinolone-
resistant ST131 isolates, first emerged around 2000 and
has since expanded rapidly around the world [15].
The global dissemination of ST131 and its subclones
is not well understood. Possible microbiologic contribu-
tors include the clone’s enhanced transmissibility, its
increased virulence, its resistance to multiple antibiotics,
and its success at colonizing the human body [8].
In certain healthcare settings, there is a high
colonization pressure with ST131, and this likely facilitates
patient-to-patient transmission. Long-term care facilities
may serve as reservoirs of this clone [16, 17]. At 2 long-
term care facilities in Minnesota, 24 % of residents were
colonized with ST131, and molecular analysis
demonstrated evidence of intra-facility and inter-facility
transmission [17]. Single-center studies at different acute
care hospitals found that 50 % of inpatients are carriers
[18] and that 13 % of stool samples sent to the microbiol-
ogy laboratory grew E.coli ST131 [19].
Antibiotic-prescribing practices are probably also con-
tributing to the spread of ST131. In a population-based
cohort study, multivariable analysis showed that ST131
carriage was predicted by older age, healthcare exposure,
and prior antibiotic use [13]. Specifically, prior use of
fluoroquinolones, macrolides or extended-spectrum
cephalosporins was predictive [13]. Other studies have
found that prior fluoroquinolone-exposure is a risk
factor for fluoroquinolone-resistant E.coli, but these
studies did not describe the sequence type of the infect-
ing strains of E.coli [2, 20, 21].
It’s unclear why the frequency of FQ-NS significantly
varied across Census Divisions within the VHA over
time. These differences may reflect broad ecological
trends beyond the VHA patient cohort. Alternately,
specific infection control and antibiotic-prescribing
practices within VHA may be influencing the spread of
these strains of E.coli. Future research could examine
Fig. 1 Region-specific changes in FQ-NS among E.coli BSIs in the Veterans Health Administration, 2003–2013
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whether use of specific antibiotic agents varies across
regions and, if so, whether the variations in antibiotic
usage help explain the variability in FQ-NS.
There are several clinical implications to these changing
resistance patterns among E.coli. Patients undergoing
transrectal prostate biopsy typically receive fluoroquiono-
lone prophylaxis. In one study, colonization with
fluoroquinolone-resistant E.coli was the most important
host characteristic associated with infection after transrectal
prostate biopsy. Nearly two-thirds of these resistant strains
were ST 131 [22]. A survey of Infectious Disease physicians
found that there is a perceived increase in the incidence of
infections after transrectal prostate biopsies [23]. Further-
more, rising rates of fluoroquinolone-resistant E.coli limit
options for empiric antibiotic therapy. Among patients with
E.coli bacteremia, inappropriate empiric antibiotic therapy
was associated with worse outcomes in some [24, 25] but
not all [26, 27] studies.
Our study has some limitations. First, the cohort
included older patients who were predominantly male. As
a result, the trends we observed may not be generalizable
to other populations. Second, we have argued that ST131
is contributing to the changing epidemiology of E.coli, but
we did not perform any microbiologic typing. A prior
study, however, has demonstrated that ST 131 is prevalent
within VHA [12].
Conclusion
In conclusion, there has been a universal increase in
FQ-NS among E.coli BSIs within VHA, and the rate of
increase has varied across Census Divisions. These find-
ings reinforce the importance of using local data to
develop and update local antibiograms and antibiotic-
prescribing guidelines.
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Fig. 2 Secular trends in FQ-NS among E.coli BSIs within 9 Census Divisions of VHA, 2003–2013
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